Inactive Instrument

Highlights Egalet Corp Nasdaq

Equities

US28226B1044

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Assertio Therapeutics, Inc. completed the acquisition of Zyla Life Sciences.	20-05-19	CI
Zyla Life Sciences Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-14	CI
Zyla Life Sciences Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-26	CI
Assertio Therapeutics, Inc. entered into an agreement to acquire Zyla Life Sciences for $20.9 million.	20-03-15	CI
Zyla Life Sciences Announces Unaudited Consolidated Earnings Results for the Third Quarter Ended September 30, 2019	19-11-13	CI
Zyla Life Sciences Provides Sales Guidance for the Year 2019	19-08-13	CI
Zyla Life Sciences Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-13	CI
Egalet Corporation Reiterates Revenue Guidance for the Year 2019	19-05-16	CI
Adare Pharmaceuticals, Inc. entered into an agreement to acquire ParvuletTM Technology Platform from Egalet Corporation.	19-04-14	CI
Egalet Corporation Reports Earnings Results for the Full Year Ended December 31, 2018	19-03-29	CI
Egalet Corporation Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	18-11-19	CI
Egalet Corporation Notifies U.S. Food and Drug Administration About Discontinuing the Manufacture and Promotion of Arymo ER	18-09-28	CI
Egalet Corporation Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2018; Provides Earnings Guidance for the Year 2018	18-08-08	CI
Egalet Seeks Acquisitions	18-05-10	CI
Egalet Corporation Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018	18-05-08	CI
Egalet Corporation Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2017	18-03-12	CI
Egalet Corporation Announces ARYMO® ER Data Published in Current Medical Research and Opinion Journal	18-01-29	CI
Egalet Announces Positive Top-Line Results from Phase 3 Study Evaluating Efficacy and Safety of Egalet-002 in Patients with Moderate-to-Severe Chronic Low Back Pain	17-11-28	CI
Egalet Announces Positive Top-Line Results from Phase 3 Safety Study Evaluating Safety of Egalet-002	17-11-16	CI
Egalet Corporation Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	17-11-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Egalet Corp Nasdaq

Equities

US28226B1044

Highlights

Filters